この資料は、モデルナ（マサチューセッツ州ケンブリッジ）が2025年6月30日（現地時間）に発表したものを日本語に翻訳したもので、報道関係者の皆さまに参考資料として提供するものです。資料の内容および解釈については、英語が優先されます。英語版は、 ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

The preservative is in a small share of flu shots and has been studied for decades. Experts say it’s safe — despite Kennedy’s long opposition.

"This is a very clear effort to shine a light on this anti-vaccine trope: that thimerosal is somehow dangerous.” ...